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Abstract 
Studies of the biofilm life cycle can identify novel targets and strategies for improving 
biofilm control measures. Of particular interest are dispersal events, where a 
subpopulation of cells is released from the biofilm community to search out and 
colonize new surfaces. Recently, the simple gas and ubiquitous biological signaling 
molecule nitric oxide (NO) was identified as a key mediator of biofilm dispersal 
conserved across microbial species. Here, we review the role and mechanisms of NO 
mediating dispersal in bacterial biofilms, and its potential for novel therapeutics. In 
contrast to previous attempts using high dose NO aimed at killing pathogens, the use 
of low, non-toxic NO signals (picomolar to nanomolar range) to disperse biofilms 
represents an innovative and highly favourable approach to improve infectious disease 
treatments. Further, several NO-based technologies have been developed that offer a 
versatile range of solutions to control biofilms, including: (i) NO-generating 
compounds with short or long half-lives and safe or inert residues, (ii) novel 
compounds for the targeted delivery of NO to infectious biofilms during systemic 
treatments, and (iii) novel NO-releasing materials and surface coatings for the 
prevention and dispersal of biofilms. Overall the use of low levels of NO exploiting 
its signaling properties to induce dispersal represents an unprecedented and promising 
strategy for the control of biofilms in clinical and industrial contexts.  
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Increased antimicrobial tolerance in biofilms is the basis for chronic 
infections and failed antibiotic therapies 
Antibiotic and antimicrobial strategies have traditionally been evaluated using 
suspension cultures of homogenous planktonic bacteria. However, in nature most 
bacteria live predominantly in heterogeneous multicellular biofilm communities 
encapsulated in a self-produced matrix of extracellular polymeric substances (EPS), 
while the free-swimming planktonic cells appear to be associated with a dispersal 
phase necessary to colonise new habitats. The biofilm lifestyle confers bacteria with 
greatly increased resistance compared to their planktonic counterparts, showing up to 
10,000 fold higher tolerance towards immune defences, biocides and antibiotics [1-3], 
rendering biofilm infections extremely difficult to eradicate. Thus the formation of a 
biofilm often leads to persistent and chronic infections, which greatly increase 
morbidity and mortality. Bacterial biofilms are estimated to be the cause of 80% of all 
clinical infections (e.g. reviewed in [4]). The mechanisms of biofilm tolerance are still 
not fully understood but appear to involve a combination of physical effects together 
with specific and non-specific genetic determinants. Firstly, the biofilm EPS matrix 
provides a protective barrier by both reducing the penetration of antibiotics [5] and 
accumulating extracellular defence compounds such as -lactamase enzymes [6], as 
well as guarding biofilm bacteria from macrophage engulfment and killing [7]. 
Secondly, within the biofilm, bacteria exhibit a high level of tolerance, either: (i) via 
expression of biofilm-specific traits such as periplasmic antibiotic-binding 
polysaccharides [8]; (ii) due to upregulation of enzymes to protect against endogenous 
oxidative stress [9]; or (iii) as a result of genetic modifications. The latter may occur 
in a non-specific manner due to increased frequency of mutations in biofilms that can 
lead to new resistance traits, e.g. constitutive expression of efflux pumps [10], or via 
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horizontal gene transfer when an invading pathogen acquires resistance genes from a 
commensal community [11]. Further, rapid adaptive induction of antibiotic resistance 
genes in cells at the biofilm peripheries can also serve to protect the rest of the biofilm 
community [12]. Thirdly, tolerance in biofilms is enhanced by the presence of a high 
number of persister cells. Nutrient gradients established within biofilm structures lead 
to starvation responses inducing a number of cells to switch to a transient antibiotic-
tolerant persister phenotype, which can survive antibiotic treatments and rapidly 
resume growth once the treatment is stopped [13]. Antibiotic treatments are not only 
inefficient at controlling biofilms but exposure to sub-inhibitory concentrations of 
many antibiotics can also result in increased biofilm formation (reviewed in [14]), a 
process that is likely to have clinical relevance in numerous infectious diseases. 
Accordingly there is an urgent need to develop novel therapeutics and strategies to 
control biofilms and overcome biofilm resistance. 
 
Inducing the natural biofilm dispersal response to control biofilm-
related infections  
One promising approach towards novel biofilm control measures is to study and target 
endogenous mechanisms that regulate the biofilm life cycle (Fig. 1A). Biofilm 
formation is a multi-stage process that involves the coordinated differentiation of cells. 
Following initial attachment, mediated by bacterial motility and cell surface 
appendages, such as pili and fimbriae that interact with abiotic and biotic surface 
materials, bacteria produce abundant EPS comprised of polysaccharides, proteins, 
extracellular nucleic acids, lipids and ions such as Ca2+, which irreversibly commit the 
cells to the surface. During maturation, biofilms establish complex 3D structures 
comprised of highly differentiated bacteria, rendering the biofilm environment and the 
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bacterial communities highly heterogeneous, including steep nutrient and oxygen 
gradients. The final stage of biofilm development involves the coordinated release of 
differentiated, motile, chemotactic cells known as dispersal cells (reviewed in [15]). 
These specialized cells can colonize new surfaces and restart the biofilm life cycle. In 
several bacteria, biofilm dispersal correlates with the programmed death of a 
subpopulation of cells in mature microcolonies [16]. Surviving cells are then able to 
escape through break out points, leaving behind hollow structures in the biofilm. 
Dispersal events are generally thought to benefit the biofilm by releasing 
phenotypically diverse cells for the colonisation of new surfaces and by limiting 
overcrowding in a densely populated and genetically diversified mature biofilm [17]. 
 
Several molecular triggers have been identified that can induce the transition from a 
sessile, surface associated or suspended biofilm phenotype to a free-swimming 
dispersal phenotype, including: (i) environmental and physiological cues such as 
nutrient [18-20] or oxygen [21] availability, low concentrations of nitric oxide (NO) 
[22-24], iron levels [25, 26], and D-amino acids [27]; (ii) cell-cell communication 
signals such as quorum sensing (QS) acyl-homoserine lactone signals [28], 
autoinducing peptides [29] and diffusible fatty acids [30, 31]; and (iii) intracellular 
messengers such as cyclic di-GMP (c-di-GMP), which has emerged as a central 
element in the complex regulatory network controlling the switch between biofilm 
and planktonic bacteria [32], as well as cAMP, which was previously known to 
control the stringent response and was recently found to be implicated in biofilm 
formation and dispersal [33, 34]. Upon sensing a dispersal cue, bacteria can activate a 
range of cellular effectors that lead to dispersal, including the secretion of enzymes 
and surfactants that solubilise and degrade EPS components [35-37]. Finally, 
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induction of the dispersal response activates expression of motility mechanisms such 
as flagella and pili and proteins involved in chemotaxis [38, 39]. Dispersal is thus a 
highly regulated process that requires recruitment of the cellular machinery and 
energy resources to escape from the biofilm.  
 
Manipulation of the endogenous biofilm development program, by inducing dispersal 
signals, has become a preferred strategy for developing novel control strategies in 
recent years. For instance, 2-aminoimidazole derivatives targeting QS have been 
designed and found to disperse established biofilms [40, 41]. Proof of concept studies 
showed that in vivo manipulation of c-di-GMP levels can effectively clear (by 
decreasing c-di-GMP) or prolong (by increasing c-di-GMP) Pseudomonas aeruginosa 
infections in murine models [42, 43]. Modification of the BdcA protein to enhance its 
c-di-GMP binding, thus reducing the intracellular c-di-GMP concentration, caused 
nearly complete removal of biofilms via dispersal in vitro [44]. Of particular interest 
is NO, a simple and versatile dispersal signal that is highly conserved across biofilm 
species. Much progress has been made in recent years to design efficient NO delivery 
strategies making it an outstanding candidate for novel therapeutic strategies. This 
review focuses on the discovery and use of NO for inducing biofilm dispersal. 
 
Recent discovery of a key physiological signal for biofilm dispersal: 
nitric oxide (NO) 
NO is produced endogenously during the biofilm life cycle to induce dispersal and 
trigger the transition to a planktonic lifestyle 
NO is a ubiquitous gas and reactive lipophilic radical that can freely diffuse into cells. 
Its signaling role in regulating dispersal of bacterial biofilms was first discovered 
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while studying the biofilm life cycle of P. aeruginosa, where it was found to be 
produced at the same time and location as cell death and dispersal [22] (Fig. 1A). The 
use of a range of fluorescent dyes for detecting specific reactive oxygen and nitrogen 
species first indicated NO as the key mediator of cell death. This was confirmed by 
genetic studies demonstrating that dispersal events in biofilms are regulated by the 
endogenous production of NO [22]. A mutant strain unable to express nitrite 
reductase (NIR) required for production of NO did not show cell death and dispersal, 
whereas a mutant strain unable to scavenge NO (impaired in production of NO 
reductase, NOR) exhibited increased cell death and dispersal compared to the wild 
type [22]. Further, it was found that adding NO back to biofilms, by using donor 
compounds that spontaneously release NO in solution, showed that NO, at low, non-
toxic concentrations in the picomolar to nanomolar range, triggered dispersal and the 
transition to the planktonic mode of growth. Importantly, exposure to low doses of 
NO restored the sensitivity of biofilm and dispersed bacteria towards several classes 
of antimicrobial agents, greatly increasing their efficacy (Fig. 2). 
 
NO-mediated dispersal is conserved across species 
Dispersal responses to NO have been observed in a range of monospecies biofilms. 
For instance addition of NO donors was shown to induce dispersal in biofilms of P. 
aeruginosa, Escherichia coli, Vibrio cholerae, Bacillus licheniformis, Serratia 
marcescens, Fusobacterium nucleatum [23], Shewanella woodyi [24], Neisseria 
gonorrhoeae [45] and a marine Pseudoalteromonas species [46], and in Vibrio 
fischeri addition of a NO scavenger prevented dispersal of aggregates [47]. Exposure 
to nitrite inhibited biofilm formation by Staphylococcus aureus, presumably through 
generating NO and inducing dispersal [48]. In Bacillus subtilis [49], changes in 
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endogenous production of NO resulted in loss of biofilm biomass. In Legionella 
pneumophila, a NO responsive sensor protein was found to mediate reduction in 
biofilm biomass [50]. Nitrifying biofilms also appear to be responsive to NO, for 
instance Nitrosomonas europaea biofilms were previously found to disperse in 
response to low NO levels [51]. In Pseudomonas putida studies showed that 
heterologous expression of a NO synthase (NOS) enzyme resulted in increased 
motility and biofilm dispersal [52]. Further, NO can also induce dispersal in 
multispecies biofilms. Addition of low dose (20-500 nM) NO donors caused dispersal 
of mixed species microbial biofilms formed in drinking water and recycled-water 
systems and on reverse osmosis water filtration membranes [23]. Suspended biofilm 
aggregates in expectorated sputum from chronically infected cystic fibrosis (CF) 
patients were dispersed by using NO donors [53]. Thus NO-mediated biofilm 
dispersal appears to be well conserved across bacterial species. Paradoxically, some 
studies have demonstrated the opposite effect where the addition of NO stimulated 
biofilm formation, for instance in Shewanella oneidensis [54] and the rhizobacterium 
Azospirillum brasilense [55]. It is possible that NO may not induce dispersal 
responses in some species, for instance in the context of host-microbe symbiotic or 
mutualistic relationships [56]. Intriguingly, disaggregation, dispersal and inhibition of 
attachment induced by NO have also been observed in several eukaryotic organisms, 
including fungi [23, 57], amoeba [58] and algal zoospores [59] (Table 1), which 
suggests that NO may be an ancient and highly conserved regulator of dispersal [60]. 
 
NO signaling involves the secondary messenger c-di-GMP 
To elucidate the regulatory mechanisms involved in NO-mediated biofilm dispersal, 
transcriptomic analysis of the cellular response to low levels of NO were performed in 
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P. aeruginosa biofilms. These studies revealed that NO signaling is part of a global 
regulatory network that controls the switch between biofilm and planktonic 
phenotypes and involves the secondary messenger c-di-GMP [39]. NO was found to 
decrease intracellular levels of c-di-GMP and stimulate phosphodiesterase (PDE) 
activity in cell-free extracts, the latter suggesting posttranslational regulation [39]. 
The ubiquitous messenger c-di-GMP functions as a central regulator of many 
important bacterial processes, including biofilm formation, virulence and dispersal 
(recently reviewed in [32, 61]). Intracellular levels of c-di-GMP are controlled 
through the opposing activities of diguanylate cyclases (DGC), for the synthesis of c-
di-GMP, and PDEs, for its degradation. These are encoded by a conserved GGDEF 
domain and EAL or HDGYP domain containing genes, respectively. Many bacterial 
genomes encode multiple DGCs and PDEs often associated with other putative 
signaling domains, suggesting that their enzymatic activities may be responsive to 
different environmental cues. Downstream cellular targets of c-di-GMP include 
repression of EPS production, activation of EPS degrading enzymes and motility. A 
number of effectors of c-di-GMP signaling have been identified, such as transcription 
factors, PilZ domain and degenerate GGDEF and EAL domain-containing proteins, as 
well as mRNA riboswitches [61]. A link between NO and c-di-GMP has been 
established in several bacterial species in addition to P. aeruginosa, including S. 
woodyi [24], L. pneumophila [50], Pseudoalteromonas atlantica [62] and E. coli [63]. 
In E. coli, NO was found to induce motility and decrease surface attachment upon 
binding to the transcription repressor NsrR [64], although it is not clear if NsrR is 
linked to c-di-GMP or whether it operates via an independent pathway in E. coli. 
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In P. aeruginosa several c-di-GMP specific PDEs have been identified that appear to 
be involved in NO-mediated dispersal, including DipA, RbdA and NbdA [65, 66]. 
Further, NO signaling was shown to require the chemotaxis regulator BdlA [39], as 
well as the periplasmic protease LapG (dispersal in response to NO donors in in vitro 
batch and continuous flow P. aeruginosa biofilm assays was fully inhibited in the 
lapG knockout mutant strain compared to wild type, unpublished data), which in P. 
putida and Pseudomonas fluorescens was found to be repressed by a c-di-GMP 
receptor protein LapD and activated when intracellular c-di-GMP levels decreased [67, 
68]. Although a receptor for NO associated with a c-di-GMP PDE remains to be 
identified in P. aeruginosa, such regulatory systems have been identified in S. woodyi 
[24]. S. woodyi encodes a heme nitric oxide/oxygen binding (HNOX) protein, which 
when complexed with NO binds to and activates a PDE enzyme resulting in dispersal 
(Fig. 1B). HNOX domains are conserved hemoproteins that are highly sensitive to 
NO, producing responses at femtomolar levels in Clostridium botulinum [69]. They 
are found in several Gram-negative and Gram-positive bacterial genomes and are 
often associated with a DGC or PDE [70]. However many bacterial strains known to 
disperse in response to NO, including P. aeruginosa and E. coli, do not have HNOX 
domain suggesting other systems can sense and transduce NO signals. Similarly, 
Gram-positive strains such as S. aureus do not possess any GGDEF, EAL or HDGYP 
domain, suggesting that in some organisms NO-mediated dispersal may operate via a 
signaling cascade independent of the secondary messenger c-di-GMP. 
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Dysregulation of NO production by the host immune system leads to 
chronic infection and disease 
NO has been known to play an important role in the immune system and host 
defences against pathogenic bacteria for some time. Early studies showed that host 
tissues produce NO using nitric oxide synthase (NOS) enzymes from L-arginine after 
recognition of bacterial invasion [71-73]. Both constitutively expressed (cNOS) and 
inducible (iNOS) NOS are involved in immunity. In macrophage and epithelial cells, 
iNOS enzymes are activated by bacterial lipopolysaccharides (LPS) and inflammatory 
cytokines (e.g. IFN-, IL-1, and TNF-) [74].  
 
In some cases, impairment of NOS function can lead to infectious disease. The cause 
of NOS malfunction may originate from the host or from the bacteria. For example, 
invading pathogens such as E. coli [75] or Salmonella typhimurium [76] can avoid 
host defences by secreting effectors that inhibit iNOS. Helicobacter pylori was found 
to secrete arginase to inhibit NO production in gastric mucosa [77]. In the oral cavity, 
NO production normally occurs during plaque deposition but in patients affected by 
smoking, where NO levels are reduced, higher bacterial counts are observed [78]. 
 
Cystic fibrosis (CF) lungs 
NOS activity and generation of NO is required for clearance of infections in the 
respiratory tract [79]. In the lungs of patients suffering from CF, epithelial cells fail to 
produce NO in response to pathogen invasion and bacterial LPS sensing [80, 81]. 
Impaired NO production may be due to reduced NOS expression, including both 
iNOS [80, 82, 83] and possibly cNOS [84], as well as reduced availability of the NOS 
substrate L-arginine, possibly due to increased arginase activity in CF airways [85]. 
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This inability to produce NO in response to pathogen invasion in CF patients appears 
to play a major role in the establishment of chronic infections, and compromised NOS 
activity has even been suggested as the primary reason for the poor antimicrobial 
defence of CF lungs [86]. In vitro studies using human airway epithelial cells from a 
CF patient showed reduced P. aeruginosa adhesion and infection in CF cells 
transfected with human iNOS cDNA compared to cells without iNOS [87]. Further, in 
these experiments while recombinant iNOS did not reduce internalisation of adhered 
bacteria, internalised cells were efficiently killed, suggesting that NO production 
mostly regulates adhesion as well as killing of cells that have infiltrated the 
epithelium.  
 
NO and inflammation 
NO plays an important role in regulating inflammatory responses. Dysregulation of its 
production in chronically infected host tissues can lead to immunopathology [88]. In 
healthy patients, NO can act as an autoregulatory feedback inhibitor serving to limit 
tissue damage after the onset of inflammation. At high levels, NO can inhibit iNOS 
expression in macrophages and terminate the inflammatory process [89]. The 
mechanisms underlying this regulation have recently been uncovered and found to 
involve S-nitrosylation of the inflammasome protein NLRP3 [90]. Thus it was 
suggested that impaired iNOS activity could potentially exacerbate autoimmune 
diseases including colitis, arthritis and multiple sclerosis [91]. In CF patients, lack of 
iNOS has also been linked to inflammation disorders [92]. Due to its role in 
inflammation and because it can be measured quickly and non-invasively in the 
respiratory airways, exhaled NO has become an important diagnostic marker for 
inflammatory airway conditions such as asthma and bronchitis [93, 94]. 
 13
 
Adjunctive low dose NO combined with antibiotics: a promising new 
clinical strategy for biofilm control 
Treatments to induce biofilm dispersal with NO and effectively inactivate dispersed 
bacteria with antibiotics 
The ability of NO to induce the signaling cascade involving stimulation of PDE 
activity and decreased intracellular c-di-GMP leading to dispersal of biofilms offers 
great promise for developing novel and efficient therapeutics for controlling biofilm-
related infections and for overcoming biofilm resistance. While exposure to low doses 
of NO alone appears to be non-toxic to bacteria, the released planktonic cells and cells 
still residing on surfaces both show increased susceptibility to a range of antibiotics 
and antimicrobials [23, 39, 95]. Thus NO-based anti-biofilm strategies probably 
benefit from combined treatments with standard antibiotic therapies to clear infections. 
Before considering NO as a standalone therapeutic, further studies are needed to 
determine whether exposure to low doses of NO in a host environment can facilitate 
recruitment of immune defences capable of clearing the dispersed cells.  
 
Biofilm-related diseases are highly diverse as biofilms can form on both living tissues, 
e.g. lungs, nose (rhinosinusitis), urinary tract, ears (otitis media), heart (endocarditis), 
oral cavity (plaque, gingivitis) or wounds, as well as abiotic surfaces, e.g. dialysis 
catheters, prosthetic implants or contact lenses [4]. This variety of conditions makes it 
difficult to develop antibiofilm treatments that could be applied for treating multiple 
diseases. NO-based strategies to disperse biofilms will benefit from a broad range of 
delivery methods (reviewed below) that can be specifically adapted on a case-by-case 
basis.  
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At higher levels, NO may be effective at killing biofilms 
At physiological concentrations, in the picomolar and nanomolar range, NO serves 
multiple signaling roles in both the host and pathogenic organisms. However, at 
higher concentrations NO can be converted to a number of more reactive derivatives, 
known collectively as reactive nitrogen species, which can have cytostatic and 
cytotoxic effects on pathogens as well as host cells [96]. These can cause damage to 
nucleic acids and proteins through nitrosylation (adding an NO group) or nitration 
(adding an NO2 group) of amine, thiol and tyrosine residues, as well as metal centres 
[96]. At elevated concentrations, the high diffusivity and multiple modes of action of 
NO make it a broad-spectrum antimicrobial agent that could kill biofilms of Gram-
negative and Gram-positive bacteria. In vitro experiments showed that exposure to 
200 ppm NO gas (~8 µM NO) for up to 5 h could fully eradicate cultures of clinical 
isolates of S. aureus, methicillin-resistant S. aureus (MRSA), E. coli, Group B 
Streptococcus, P. aeruginosa and Candida albicans [97]. The potential of intermittent 
exposure to high levels of NO gas has been assessed in animal trials using rats. NO 
was delivered at 160 ppm (~7 µM NO) for 30 min every 4 h to rats with P. 
aeruginosa airway infection, and the results showed that the NO treatment was able to 
reduce the infection by more than 2 log [98]. Exposure to NO gas at 500 ppm (~20 
µM NO) for 60 s every 24-48 h of external wounds colonised by S. aureus led to 
faster wound healing by 30%, compared to controls [99]. Wound dressings that 
release NO levels typically at 500 ppm appeared to be efficient at killing biofilms of 
nosocomial pathogens Acinetobacter baumannii, MRSA, and P. aeruginosa when 
assessed in in vitro experiments [100]. The use of toxic NO has also been investigated 
for treatment of urinary tract infections, where the addition of 10 mM ascorbate and 
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nitrite at 50 µM to 5 mM, which under these conditions generate equimolar NO, 
cleared E. coli infections in artificial urine and in an urinary tract model [101, 102]. 
Another study demonstrated the effectiveness of NO-charged catheters, typically 
releasing 2 to 60 µM NO, in preventing E. coli infections [103]. 
 
Several concerns have been raised when using NO as a bactericidal agent. Firstly, at 
high concentrations NO can be toxic to tissues and inhibit healing. Because NO can 
act as an immunosuppressant that limits inflammation, high levels could prematurely 
halt healing and reduce macrophage activity against infections. Further, during wound 
treatments excessive NO could be inhibitory to angiogenesis, decreasing endothelial 
cell and lymphocyte proliferation [104, 105]. Side effects of nitrosative stress in host 
tissues include the generation of carcinogenic N-nitrosamines [106]. In the lungs, high 
levels of NO can transfer to the blood and cause methaemoglomia [107]. Recently the 
safety of delivery and the physiologic effects of intermittent exposure to 160 ppm NO 
gas three times daily for 30 min for 5 days have been assessed in clinical trials. While 
a first cohort of healthy individuals appeared to tolerate the treatment well [108], in a 
second trial with CF patients, detrimental side effects were reported in several of the 
eight patients who received NO that included increased methaemoglomia, dry mouth, 
and one case of reduced lung function (forced expiratory volume in 1 s, FEV1 max < 
10%) [109]. Second, at elevated levels, NO may induce defence mechanisms in 
bacteria rendering them more tolerant to antibiotics. Thus in P. aeruginosa, while 
exposure to low concentrations of NO induced biofilm dispersal, treatment with 
higher concentrations in the micromolar to millimolar range resulted in increased 
biofilm formation, presumably as an adaptive response to protect against nitrosative 
stress [22]. In B. subtilis, 5 s exposure to 30 µM NO was found to enhance defence 
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against oxidative stress by depleting free cysteine and activating catalase [110]. In 
Salmonella, 750 µM NO donor spermine NONOate was found to block respiration, 
which induced an accumulation of NADH that protected against oxidative stress [111]. 
The same treatment was also shown to impair energy-dependent drug uptake after 
causing an arrest in respiration, which then led to increased resistance towards 
aminoglycoside antibiotics [112]. Finally, at high levels NO may directly react with 
antibiotic compounds leading to their inactivation [113]. Therefore the effectiveness 
of toxic levels of NO to kill biofilms may be strongly dependent on the bacterial 
species and infection conditions and may elicit undesirable secondary effects that 
could compromise clearance of the infection. In contrast, increased antibiotic 
resistance is not expected when using low, non-toxic concentrations of NO in the 
picomolar to nanomolar range to induce dispersal. 
 
NO delivery methods 
Due to its reactivity towards a wide range of molecules, including metalloproteins, 
heme and non-heme iron centres, thiols and amines, as well as oxygen and free radical 
species such as superoxide (O2
–•), NO has a half-life of only a few seconds in 
biological systems [114]. In order to be effective, NO needs to be available in the 
immediate vicinity of pathogenic biofilms. The method of delivery of NO to 
infectious biofilms is therefore crucial and can conceivably be achieved by several 
means. 
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Use of NO gas 
If applicable, NO can be directly applied as a gas to infection sites exposed to air. NO 
gas has been used to treat skin infections, most notably leg ulcers [115]. Inhaled NO 
gas was approved as therapeutic agent by the US Food and Drug Administration 
(FDA) in 1999 and the European Medicine Evaluation Agency and European 
Commission in 2001. It has since been used as a pulmonary vasodilator in treating 
pulmonary hypertension, including in patients with chronic obstructive pulmonary 
disease (COPD) [116, 117]. However, the effect of inhaled NO on bacterial infections 
during these treatments was not investigated. Previous studies by two different 
research teams showed that exposure to 40 ppm NO in air [118] or 10 ppm NO in 
100% oxygen [119] for 24 h reduced P. aeruginosa infiltration and helped clear lung 
infections in rats, decreasing bacterial load by 1.7 and 2 log, respectively. In the latter 
study, 10 ppm NO was also found to increase influx of inflammatory cells into the air 
space of infected rats [119]. Recently, the first clinical trial was conducted to evaluate 
the use of low dose inhaled NO gas combined with standard intravenous ceftazidime 
and tobramycin antibiotic therapy for the disruption of P. aeruginosa biofilms in 12 
patients with CF. The results demonstrated that patients who received NO gas at 5-10 
ppm (~200 nM NO) for 8 h daily during 7 days concomitant with standard 
ceftazidime and tobramycin treatments showed significant reductions, by 3.5 log in 
the number of Pseudomonas biofilm aggregates and marginal improvement in lung 
function (FEV1 and forced vital capacity, FVC) compared to patients who received a 
placebo [120]. These data suggest that using NO as adjunctive therapy may be highly 
beneficial for the treatment of CF-related biofilm infections. 
 
 18
Stimulation of endogenous NO production  
The delivery of NO to infectious biofilms should be achievable by stimulating 
endogenous production, either from the biofilm cells or from the surrounding infected 
tissues. In bacteria, NO is produced from NIR enzymes in denitrifying as well as non-
denitrifying organisms [121], or from NOS enzymes using L-arginine as substrate 
[122]. Nitrate, nitrite and L-arginine have all been shown to enhance susceptibility of 
P. aeruginosa in biofilms to antibiotics by up to 2 log reduction in colony-forming 
units (CFU), presumably through an NO-mediated mechanism [123]. Exposure of S. 
aureus to nitrite, which was suggested to generate NO, prevented the formation of in 
vitro biofilms [48]. Addition of acidified nitrite, which can generate NO either 
spontaneously or from NIR activity, was found to effectively control P. aeruginosa, S. 
aureus and Burkholderia cepacia biofilms [124, 125], although in these cases high 
concentrations of nitrite (15 mM) were used and NO acted via a toxic, killing effect 
on biofilms. In preliminary clinical studies, treatments with nebulized L-arginine in 
CF patients infected with P. aeruginosa resulted in sustained improvement in lung 
function associated with significantly increased NOS activity within lung tissues, 
suggesting that the NO augmentation could potentially reduce the bacterial infection 
[126, 127]. However in these studies, the effect of increased L-arginine on P. 
aeruginosa growth was not investigated and will need to be confirmed in subsequent 
trials. 
 
Use of NO donors  
The most versatile option for the delivery of NO is to use NO-donor molecules that 
can liberate NO in vivo. Release of NO from donors can occur either spontaneously, 
upon activation by enzymatic activity or through activation under select chemical 
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conditions, e.g. pH. In general, the effective concentrations of NO delivered to the 
biofilms are estimated to be 100-1000 times lower than the concentration of NO 
donor used (Fig. 3, [23]). NO donors could potentially be administered in a variety of 
formulations, including tablets, ointments or nebulisers. Much progress has been 
made in developing usable NO donors and a large variety of compounds have been 
described in various reviews (e.g. [128, 129]). The metal nitrosyl sodium 
nitroprusside (SNP) and the organonitrate nitroglycerin are FDA-approved drugs that 
have been used for more than 50 years in the treatment of hypertension. SNP at 500 
nM has been shown to effectively disperse various single species biofilms as well as 
multispecies biofilms, including those in CF sputum [22, 23, 53]. S-nitrosoglutathione 
(GSNO), a naturally occurring S-nitrosothiol, is also used clinically as a vasodilator, 
including in the lungs of CF patients [130, 131]. An important and highly versatile 
class of NO donors are the diazeniumdiolates (NONOates). Originally created as a 
laboratory curiosity, this class of compounds has evolved in the past 15 years into a 
vast range of compounds with wide ranging chemical properties and NO release 
profiles that are potentially useful in many short- or long-term healthcare applications 
[132] (Fig. 3). NONOate chemistry allows for storage of NO as part of an engineered 
molecule whose framework can be controlled to tune the level of NO storage, rate of 
NO release and molecule size. The compounds can be used to modify polymers and 
nanoparticles and can also be engineered to include prodrug moieties for targeted NO 
delivery (see sections below). Finally, dispersal of P. aeruginosa biofilms by long-
lived aminoxyl free radicals (nitroxides), which are sterically hindered analogues of 
nitric oxide, has been demonstrated [133]. 
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Targeted delivery of NO by using β-lactam prodrug antibiotics 
Due to its short half-life in biological systems and its potential for non-selective 
reactivity towards many host targets, the use of donor compounds that spontaneously 
release NO in solution would often not be ideal for treating biofilm infections. The 
compounds could potentially have side effects and these typically polar chemicals 
would be difficult to deliver to biofilms. An innovative new class of NO-donor 
prodrugs was recently described that can liberate NO upon specific activation by 
bacterial enzymes [95, 134] (Fig. 4). The cephalosporin-3’-diazeniumdiolate 
compounds consist of a β-lactam analogue, cephalosporin, that provides a scaffold to 
prevent release of NO from an NONOate donor until activated by a substrate-tolerant, 
bacteria-specific enzyme β-lactamase. The modified cephalosporins were rationally 
designed to selectively release highly unstable NONOates (t1/2 = 2.8 s-2 min for NO 
generation) following reaction with β-lactamase, and thus trigger biofilm dispersal. 
The lead compound, DEA NONOate-Cephalosporin Prodrug (DEACP) was 
synthesised and found to be highly stable in solution and release NO upon reaction 
with commercially available β-lactamase penicillinase as well as whole cell extracts 
from P. aeruginosa that produce β-lactamases. Interestingly, release of NO was also 
triggered by non-β-lactamase-producing E. coli extracts suggesting that the 
compounds can also be activated by transpeptidases, the target enzymes of β-lactam 
antibiotics. These compounds were effective at dispersing biofilms of several 
pathogenic species including mixed species biofilms from CF sputum, and when used 
in combination with tobramycin and ciprofloxacin greatly improved the outcome of 
the antibiotic therapy [53, 95]. In these experiments, the use of DEACP at 10 µM was 
found to be more effective than at 100 µM, increasing tobramycin and ciprofloxacin 
treatments by 1.8 and 1.5 log reduction in CFU, respectively [95]. The novel and 
 21
flexible synthetic chemistry route developed for DEACP was used to access five 
additional analogues carrying variations in both the acyl-amido side chain (R1) and 
O2-alkyldiazeniumdiolate (R2) portions [134] (Fig. 5). The compounds showed 
activity similar to DEACP. Two compounds, DEACP and PyrroCP were tested for 
cytotoxicity in L929 murine fibroblast cells and showed no toxicity at 50 µM 
(DEACP) or 100 µM (PyrroCP, unpublished data), which suggests an excellent 
therapeutic window. The use of β-lactam-based prodrugs for the targeted delivery of 
NO to biofilms is immensely attractive as many cephalosporins have previously and 
continue to be used clinically [135]. The simple modification to incorporate a 
diazeniumdiolate NO donor may represent an effective method for treating biofilm-
based chronic infections. 
 
NO polymers and nanoparticles 
Nanoparticle drug delivery has been widely studied as a means for increasing drug 
solubility and tissue specificity. The utility of nanoparticles arises from their various 
physicochemical properties (e.g., hydrophobicity, charge, size), which can be tuned 
by varying synthetic precursors and procedures. Silica- and gold-based nanoparticles 
have been developed that release low or high levels of NO [136-139] and show 
effectiveness against biofilms [140]. Nanoparticles also offer the advantage that they 
can be combined with other active molecules, such as antimicrobial agents, e.g. long 
chain quaternary ammonium salts [141]. NO-releasing polypropylenimine dendrimers 
have been developed which allow higher levels of NO release per ‘backbone’ 
molecule over traditional NO donors [142]. NO releasing polymers and nanoparticles 
could be used either as coatings to prevent biofilm formation on surfaces such as 
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catheters, prosthetic implants or contact lenses as well as industrial surfaces, or 
delivered in formulation either systemically or topically to treat biofilms on tissues.  
 
NO-QS inhibitor dual-action hybrid compounds 
Another important signaling pathway in biofilms is the quorum sensing (QS) system. 
QS regulates virulence, biofilm formation and dispersal in a range of organisms [143]. 
NO and QS-mediated regulation appear to share common molecular mechanisms, as 
exemplified in P. aeruginosa where QS deficient strains were found to accumulate 
more NO [144, 145]. This raises the intriguing possibility of interfering with multiple 
biofilm regulatory pathways using combinations of QS inhibitors and NO donors as a 
strategy towards therapeutics for controlling biofilms and bacterial virulence. A wide 
range of synthetic and natural product-based QS inhibitors have been identified in the 
last two decades, including the halogenated furanones isolated from the marine red 
algae Delisea pulchra which show highly potent QS inhibition and virulence 
attenuation activities [146]. Recently, novel dual-action furanone-NO donor hybrid 
compounds have been designed and synthesized. Two compounds were found to have 
both QS inhibition and NO releasing properties and were effective antibiofilm agents 
[147]. 
 
Surface modification for biofilm prevention and dispersal  
The formation of biofilms on abiotic surfaces is a major clinical concern as biofilms 
on prosthetic implants, catheters or contact lenses, for example, can act as reservoirs 
for pathogenic bacteria leading to chronic and severe infections. NO releasing 
materials and coatings were originally developed to prevent platelet aggregation and 
improve biocompatibility of biological implants, such as vascular grafts (artificial 
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blood conduits) [148, 149]. Newer sol-gel NO releasing coatings based on NONOates 
have been developed that are compatible with artificial prosthetic implants and 
display antibacterial properties. The coatings were capable of inhibiting adhesion of 
biofilm bacteria, e.g. P. aeruginosa, S. aureus, and S. epidermidis [150, 151]. Polymer 
coatings that allow for modulation of NO release, controlled either by light, (e.g. S-
nitrosothiols [152] or metal nitrosyls [153]) or by an electric pulse [154] have also 
been developed. Finally, coatings capable of catalytically generating NO via 
conversion of endogenous substrates such as S-nitrosothiols or nitrite are attractive for 
long-term applications since they are not limited by a finite reservoir of NO 
embedded in the surface [155, 156]. 
 
Future perspectives  
The role of NO as a signaling molecule is vast. First discovered in the 1980s for its 
role in regulating vasodilation via the activation of soluble guanylate cyclase, NO has 
since emerged as a universal signal regulating a plethora of physiological functions in 
living organisms [157]. Its importance in human physiology was recognised with a 
number of awards and NO was named ‘molecule of the year’ by Science in 1992 
[158]. The diffusivity of NO across cell membranes and its reactivity towards a range 
of target sites stand out as unique properties in signal transduction that allow rapid 
spreading and amplification of an initial cue and the coordination of a subset of 
adjacent cells. The signaling role of NO in regulating biofilm dispersal across 
microbial species offers an unprecedented opportunity to develop novel treatments to 
induce biofilm dispersal and improve treatments for chronic infections. Since the 
mechanisms linked to dispersal involve non-toxic activation of a signaling pathway 
there is reduced pressure for the evolution and spreading of variant bacteria. Thus, 
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resistance is not expected to arise from low-dose NO treatments. As the signaling 
pathways are further elucidated, novel markers both from infectious biofilms and host 
tissues will be identified that will facilitate the evaluation of novel biofilm-dispersing 
compounds in in vivo studies. 
 
A range of NO donor compounds are already available that can be used as adjunctive 
therapies to improve antibiotic treatments. In addition, novel carriers, including 
nanoparticles and dual-action hybrid drugs, polymer coatings and prodrugs 
specifically designed to release NO to biofilm infection sites are being investigated. In 
the future, new compounds will be designed that exhibit multiple actions, including 
release of NO signals and/or other agents interfering with various effectors of the 
signaling cascades regulating dispersal and virulence, combined with potent antibiotic 
activity. Further, given the extreme simplicity of NO as an active ingredient, it may be 
possible to develop a wide range of targeted release chemistries for the precise 
delivery of NO signals to specific pathogenic bacteria, while leaving intact the 
commensal microbial community. 
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Figures and Tables 
 
Fig. (1). (A) The biofilm life cycle: oxygen (O2) and nutrient gradients are present in 
the mature biofilm leading to production of NO signals that trigger cell death and 
dispersal. (B) NO signals activate phosphodiesterase (PDE) activity, which leads to 
decreased c-di-GMP levels and enhanced dispersal. In Shewanella woodyi, direct 
binding of NO to an H-NOX sensor stimulating PDE activity has been demonstrated 
[24]. 
 
Fig. (2). Add-back of NO to established biofilms using the NO donor sodium 
nitroprusside (SNP) triggers dispersal and increases susceptibility to various 
antimicrobial treatments: hydrogen peroxide (H2O2), tobramycin, sodium dodecyl 
sulphate (SDS) and ultraviolet light (UV). Partly reproduced from [22]. 
 
Fig. (3). (A) Representatives from the NONOate (diazeniumdiolate) class of NO 
donors. (B) Spontaneous NO release from 100 µM PROLI/NO, DEA/NO or 
SPER/NO in 0.1 M Tris buffer (pH 7.4). Measurements were obtained using an NO 
selective electrode. Arrow indicates addition of the NO scavenger 2-phenyl-4,4,5,5,- 
tetramethylimidazoline-1-oxyl 3-oxide (PTIO). 
 
Fig. (4). Novel prodrug strategy for biofilm-targeted NO delivery [95]. (A) 
Cephalosporins bearing O2-alkyldiazeniumdiolates at the 3’ position release 
NONOate anions following reaction with bacterial -lactamases. (B) Electrode 
measurements of NO release from DEACP in the presence of penicillinase. Arrows 
from left to right indicate addition of: 100 µM DEACP, 0.05 U / ml penicillinase, 0.1 
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U / ml penicillinase and NO scavenger PTIO. (C) Schematic drawing of DEACP 
activation and NO-induced dispersal in biofilms. Red stars denote biofilm -
lactamase enzymes. 
 
Fig. (5). Chemical structures of synthesised cephalosporin-3’-diazeniumdiolates. Half 
lives of the appended diazeniumdiolates in aqueous buffer at pH 7.4 are given. 
Compound numbers correspond to [134]. 
 
Table 1. List of microbial species dispersed by NO. 
Microbial species Description  
Manipulation of NO 
levels 
Ref 
Single species biofilms    
Pseudomonas aeruginosa Gram –ve opportunistic 
pathogen 
NO donors SNP, 
nitroxides, MAHMA 
NONOate. Mutants 
in NIR and NOR 
[22, 23, 
66, 133, 
159] 
Escherichia coli Gram –ve opportunistic 
pathogen 
NO donor SNP [23, 64] 
Fusobacterium nucleatum  Gram –ve anaerobic oral 
pathogen 
NO donor SNP [23] 
Serratia marcescens Gram –ve opportunistic 
pathogen 
NO donors SNP, 
SNAP 
[23] 
Vibrio cholerae Gram –ve pathogen, agent 
of cholera 
NO donors SNP, 
SNAP, GSNO 
[23] 
Bacillus licheniformis Gram +ve soil bacterium NO donor SNP [23] 
Shewanella woodyi  Gram –ve marine bacterium NO donor DETA [24] 
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NONOate 
Neisseria gonorrhoeae  Gram –ve pathogen NO donor SNP [45] 
Pseudoalteromonas sp. 
strain NCIMB 2021 
Gram –ve marine bacterium NO donor SNP [46] 
Vibrio fischeri Gram –ve marine bacterium NO scavenger PTIO [47] 
Staphylococcus aureus Gram +ve pathogen NO source sodium 
nitrite 
[48] 
Bacillus subtilis Gram +ve opportunistic 
pathogen 
Mutant in NOS [49] 
Legionella pneumophila Gram –ve pathogen, agent 
of legionellosis 
Mutant in H-NOX 
domain 
[50] 
Nitrosomonas europaea Gram –ve autotroph 
nitrifier 
Low NO gas [51] 
Pseudomonas putida Gram –ve soil bacterium Heterologous 
expression of NOS 
[52] 
Multispecies biofilms    
Mixed species biofilms  From water distribution 
systems and filtration 
membranes 
NO donors SNP, 
PROLI NONOate 
[23] 
Mixed species biofilm 
aggregates 
From cystic fibrosis sputum NO donor SNP [53] 
Eukaryotes    
Candida albicans Yeast; oral and genital 
infections 
NO donor SNP [23] 
Candida tropicalis  Yeast; opportunistic 
pathogen 
NO source L-
arginine; NOS 
inhibitor L-NAME 
[57] 
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Dictyostelium discoideum  Soil amoeba NOS inhibitor L-
NIO, NO gas, NO 
scavenger 
oxyhemoglobin 
[58] 
Ulva linza Algal zoospores NO donor SNAP, 
NO scavenger PTIO 
[59] 
NIR, nitrite reductase; NOR, NO reductase; SNP, sodium nitroprusside; SNAP, S-
nitroso-N-acetylpenicillamine; GSNO, S-nitrosoglutathione; NOS, NO synthase; L-
NAME, Nω-nitro-L-arginine methyl ester; L-NIO, L-N5-iminoethyl ornithine; PTIO, 2-
phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide. 
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the mature biofilm leading to production of NO signals that trigger cell death and 
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decreased c-di-GMP levels and enhanced dispersal. In Shewanella woodyi, direct 
binding of NO to an H-NOX sensor stimulating PDE activity has been demonstrated 
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Fig. (2). Add-back of NO to established biofilms using the NO donor sodium 
nitroprusside (SNP) triggers dispersal and increases susceptibility to various 
antimicrobial treatments: hydrogen peroxide (H2O2), tobramycin, sodium dodecyl 
sulphate (SDS) and ultraviolet light (UV). Partly reproduced from [2]. 
 
 
  
 
 
 
Fig. (3). (A) Representatives from the NONOate (diazeniumdiolate) class of NO 
donors. (B) Spontaneous NO release from 100 µM PROLI/NO, DEA/NO or 
SPER/NO in 0.1 M Tris buffer (pH 7.4). Measurements were obtained using an NO 
selective electrode. Arrow indicates addition of the NO scavenger 2-phenyl-4,4,5,5,- 
tetramethylimidazoline-1-oxyl 3-oxide (PTIO). 
 
 
  
 
 
 
Fig. (4). Novel prodrug strategy for biofilm-targeted NO delivery [3]. (A) 
Cephalosporins bearing O2-alkyldiazeniumdiolates at the 3’ position release 
NONOate anions following reaction with bacterial β-lactamases. (B) Electrode 
measurements of NO release from DEACP in the presence of penicillinase. Arrows 
from left to right indicate addition of: 100 µM DEACP, 0.05 U / ml penicillinase, 0.1 
U / ml penicillinase and NO scavenger PTIO. (C) Schematic drawing of DEACP 
activation and NO-induced dispersal in biofilms. Red stars denote biofilm β-
lactamase molecules. 
 
 
  
 
 
 
Fig. (5). Chemical structures of synthesised cephalosporin-3’-diazeniumdiolates. Half 
lives of the appended diazeniumdiolates in aqueous buffer at pH 7.4 are given. 
Compound numbers correspond to [4]. 
  
 
Table 1. List microbial species dispersed by NO. 
Microbial species Description  Manipulation of NO levels Ref 
Pseudomonas aeruginosa Gram –ve opportunistic 
pathogen 
NO donors SNP, 
nitroxides, MAHMA 
NONOate. Mutants 
in NIR and NOR 
[2, 5-8] 
Escherichia coli Gram –ve opportunistic 
pathogen 
NO donor SNP [5, 9] 
Vibrio cholerae Gram –ve pathogen, agent 
of cholera 
NO donors SNP, 
SNAP, GSNO 
[5] 
Bacillus licheniformis Gram +ve soil bacteria NO donor SNP [5] 
Serratia marcescens Gram –ve opportunistic 
pathogen 
NO donors SNP, 
SNAP 
[5] 
Fusobacterium nucleatum  Gram –ve anaerobic oral 
pathogen 
NO donor SNP [5] 
Candida albicans Yeast, oral and genital 
infections 
NO donor SNP [5] 
Shewanella woodyi  Gram –ve marine bacteria NO donor DETA 
NONOate 
[1] 
Neisseria gonorrhoeae  Gram –ve pathogen NO donor SNP [10] 
Pseudoalteromonas sp. 
strain NCIMB 2021 
Gram –ve marine bacteria NO donor SNP [11] 
Vibrio fischeri Gram –ve marine bacteria NO scavenger PTIO [12] 
Staphylococcus aureus Gram +ve pathogen NO source sodium 
nitrite 
[13] 
Bacillus subtilis Gram +ve opportunistic 
pathogen 
Mutant in NOS [14] 
Legionella pneumophila Gram –ve pathogen, agent 
of legionellosis 
Mutant in H-NOX 
domain 
[15] 
Nitrosomonas europaea Gram –ve autotroph 
nitrifier 
Low NO gas [16] 
Pseudomonas putida Gram –ve soil bacteria Heterologous 
expression of NOS 
[17] 
Multispecies biofilms from 
water distribution systems 
and filtration membranes  
 NO donors SNP, 
PROLI NONOate 
[5] 
CF sputum biofilm 
aggregates 
 NO donor SNP [18] 
Candida tropicalis  Yeast, opportunistic 
pathogen 
NO source L-
arginine; NOS 
inhibitor L-NAME 
[19] 
Dictyostelium discoideum  Soil amoeba NOS inhibitor L-
NIO, NO gas, NO 
scavenger 
oxyhemoglobin 
[20] 
Ulva linza Algae zoospores NO donor SNAP, 
NO scavenger PTIO 
[21] 
NIR, nitrite reductase; NOR, NO reductase; SNP, sodium nitroprusside; SNAP, S-
nitroso-N-acetylpenicillamine; GSNO, S-nitrosoglutathione; NOS, NO synthase; L-
NAME, Nω-nitro-L-arginine methyl ester; L-NIO, L-N5-iminoethyl ornithine; PTIO, 
2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide. 
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